Biotech Values

[DewDiligence]

IDIX 2009 Clinical Goals

[Updated for today’s IDX184 PR.]



HIV

Early 2009: Partner IDX899 program. (IDIX originally guided for a deal by the end of 2008 and in today’s PR says it is “[working] to finalize a partnership.”) See #msg-28959639 for musings on the terms of such a partnership.

After partnership deal is announced: Start IDX899 phase-2a combination study (IDX899+Truvada vs Sustiva+Truvada) in first- and second-line patients.


HCV

1Q09: Start IDX184 phase-2a combination study (SoC ± IDX184). (The phase-1/2 monotherapy trial, which started in late December, is a prerequisite: #msg-34763865.)

1Q09/2Q09: Report data from phase-1/2 monotherapy study. This could come at EASL or perhaps sooner (the treatment period is only three days).

April 2009: Report preliminary results of IDX184 phase-2a study at EASL.

1H09: File IND for IDX375 non-nucleoside polymerase inhibitor.

1H09: File IND for IDX136 and IDX316 protease inhibitors.